San Diego – (June 26, 2001) – OSI Pharmaceuticals, Inc. was presented with the 6th Annual Helix Award at the Biotechnology Industry Organization’‘s 2001 International Biotechnology Convention and Exhibition held at the San Diego Convention Center.

 We are delighted to receive this prestigious award and to be recognized for our achievements in 2000,  stated Colin Goddard, Ph.D., chairman and Chief Executive Officer, OSI Pharmaceuticals.  It is particularly rewarding to have our team of scientists and business professionals acknowledged for their dedication towards advancing breakthrough therapies in cancer and other serious diseases for patients around the world. 

The award was presented at the luncheon ceremony by Carl B. Feldbaum, president, Biotechnology Industry Organization (BIO), to Robert L. Van Nostrand, vice president and Chief Financial Officer of OSI Pharmaceuticals.  The major events of 2000 – Pfizer granting OSI full development and marketing rights to Tarceva(TM), our lead anti-cancer drug candidate, and two successful financings raising a total of $487 million – transformed the status and future prospects of the Company,  stated Mr. Van Nostrand.  It is an honor to be recognized by the biotech industry for our accomplishments. 

The Helix Award is jointly sponsored by the State University of New York at Stony Brook, the Center for Biotechnology and presented in conjunction with BIO. It is awarded on behalf of the Long Island Biotech community.  The Long Island biotech community is proud to promote the highest standards of achievement among biotech companies,  said Clinton T. Rubin, director, Center for Biotechnology.

The Helix Award is open to public and private U.S. or foreign-based biotechnology companies. An independent panel of judges representing the biotechnology community reviewed the submissions and KPMG LLP tabulated the results.

Background on OSI Pharmaceuticals, Inc.

OSI Pharmaceuticals is a leading biopharmaceutical company with a substantial portfolio of product opportunities for commercialization with the pharmaceutical industry. OSI utilizes a comprehensive drug discovery and development capability to facilitate the rapid and cost-effective discovery and development of novel, small molecule compounds against more than 40 gene targets.

Background on sponsors

BIO represents more than 950 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

The Center for Biotechnology is a New York State Center for Advanced Technology in Medical Biotechnology. The Center for Biotechnology was established in 1983 as a cooperative research and development partnership between universities, private industry, and New York State. Its goal has been to capitalize on the resources of New York’‘s medical biotechnology research for the purpose of fueling economic development in New York State.

SUNY Stony Brook has assumed an important role in the development of Long Island’‘s biotechnology industry through its Center for Advanced Technology in Medical Biotechnology and the Long Island High Technology Incubator program. Collectively, they have supported the establishment of more than 70 high technology companies. Eight biosciences companies have  graduated  from this program. Five are publicly traded with annual revenues in excess of $110 million. Additional information on the University can be accessed at